ADVFN Logo ADVFN

Hot Features

Registration Strip Icon for monitor ブラジル証券取引所、NASDAQ、NYSE、AMEX、LSEなどの主要取引所からの複数のリアルタイム株価を監視します。
Fortress Biotech Inc

Fortress Biotech Inc (FBIO)

1.87
-0.04
(-2.09%)
終了 1月19日 6:00AM
1.86
-0.01
(-0.53%)
取引時間後: 9:50AM

リアルタイムのディスカッションと取引のアイデア: 当社の強力なプラットフォームで自信を持って取引できます。

主要統計と詳細

通貨
1.86
買値
1.85
売値
1.99
出来高
313,348
1.86 日の範囲 1.97
1.355 52 週間の範囲 2.89
時価総額
前日終値
1.91
始値
1.97
最終取引時間
財務取引量
US$ 597,082
VWAP
1.9055
平均取引量 (3 か月)
660,658
発行済株式数
27,604,934
配当利回り
-
PER
-0.75
1 株当たり利益 (EPS)
-2.49
歳入
84.51M
純利益
-68.67M

Fortress Biotech Inc について

Fortress Biotech Inc is a biopharmaceutical company. The firm is involved in the business of acquiring, developing, and commercializing pharmaceutical and biotechnology products. Its product portfolio encompasses Targadox, Exelderm, Ceracade, Luxamend, and Dermasorb. The business activities of the g... Fortress Biotech Inc is a biopharmaceutical company. The firm is involved in the business of acquiring, developing, and commercializing pharmaceutical and biotechnology products. Its product portfolio encompasses Targadox, Exelderm, Ceracade, Luxamend, and Dermasorb. The business activities of the group are functioned through Dermatology Product Sales, and Pharmaceutical and Biotechnology Product Development. It derives the majority of its revenues from Dermatology segment. Its subsidiaries also operate in biotechnology, pharmaceutical, oncology, therapeutics sectors. 詳細を表示

セクター
Pharmaceutical Preparations
業界
Pharmaceutical Preparations
ウェブサイト
本社
Dover, Delaware, USA
設立
-
Fortress Biotech Inc is listed in the Pharmaceutical Preparations sector of the ナスダック市場 with ticker FBIO. The last closing price for Fortress Biotech was US$1.91. Over the last year, Fortress Biotech shares have traded in a share price range of US$ 1.355 to US$ 2.89.

Fortress Biotech currently has 27,604,934 shares in issue. The market capitalisation of Fortress Biotech is US$52.73 million. Fortress Biotech has a price to earnings ratio (PE ratio) of -0.75.

FBIO 最新ニュース

Mustang Bio Announces Reverse Stock Split

WORCESTER, Mass., Jan. 14, 2025 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang” or the “Company”) (Nasdaq: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s...

Fortress Biotech and Cyprium Therapeutics Announce U.S. FDA Acceptance and Priority Review of NDA for CUTX-101 for Treatment of Menkes Disease

Priority review granted for CUTX-101 with PDUFA target action date set for June 30, 2025 Cyprium is eligible to receive royalties and up to $129 million in aggregate development and sales...

Sentynl Therapeutics Announces U.S. FDA Acceptance and Priority Review of New Drug Application for CUTX-101 (Copper Histidinate) Product Candidate for Treatment of Menkes Disease

Sentynl Therapeutics Announces U.S. FDA Acceptance and Priority Review of New Drug Application for CUTX-101 (Copper Histidinate) Product Candidate for Treatment of Menkes Disease PR...

Fortress Biotech Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights

Emrosi approved by FDA on November 4 for the treatment of inflammatory lesions of rosacea in adults Cosibelimab PDUFA goal date of December 28 for potential approval to treat metastatic or...

Avenue Therapeutics Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights

MIAMI, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company focused on the development and commercialization...

Journey Medical Corporation Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights

U.S. FDA approved Emrosi™ (Minocycline Hydrochloride Extended Release Capsules, 40 mg) for the treatment of inflammatory lesions of rosacea in adults; launch expected in late Q1 or early Q2 of...

Mustang Bio Receives Positive Listing Determination from Nasdaq

WORCESTER, Mass., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang” or the “Company”) (Nasdaq: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s...

Mustang Bio Granted Orphan Drug Designation by U.S. FDA for MB-108 (HSV-1 oncolytic virus) to Treat Malignant Glioma

MB-108 (HSV-1 oncolytic virus) is active and well tolerated in patients with recurrent glioblastoma in ongoing Phase 1 clinical trial Preclinical data support a novel combination of MB-108 (HSV-1...

Journey Medical Corporation Announces U.S. FDA Approval of Emrosi™ (Minocycline Hydrochloride Extended Release Capsules, 40 mg) for the Treatment of Rosacea

SCOTTSDALE, Ariz., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Journey Medical Corporation (Nasdaq: DERM) (“Journey Medical”), a commercial-stage pharmaceutical company that primarily focuses on selling...

Journey Medical Corporation Announces DFD-29 Data Presented at 44th Fall Clinical Dermatology Conference

Poster Presented on Dermal and Systemic Pharmacokinetics of Oral DFD-29 (Minocycline Hydrochloride Modified Release Capsules, 40 mg) versus Oral Doxycycline 40 mg Capsules (Oracea®) in Healthy...

期間 †前日比前日比 %始値高値安値平均出来高VWAP
1-0.28-13.08411214952.142.151.843735521.93738916CS
40.137.514450867051.732.361.76856342.10754669CS
120.137.514450867051.732.361.416606581.96937938CS
26-0.17-8.374384236452.032.891.3555636651.86096707CS
520.063.333333333331.82.891.3554078371.8742192CS
156-32.34-94.561403508834.234.651.245067018.53496014CS
260-39.99-95.555555555641.8591.51.2466706132.98779643CS

FBIO - Frequently Asked Questions (FAQ)

What is the current Fortress Biotech share price?
The current share price of Fortress Biotech is US$ 1.86
How many Fortress Biotech shares are in issue?
Fortress Biotech has 27,604,934 shares in issue
What is the market cap of Fortress Biotech?
The market capitalisation of Fortress Biotech is USD 52.73M
What is the 1 year trading range for Fortress Biotech share price?
Fortress Biotech has traded in the range of US$ 1.355 to US$ 2.89 during the past year
What is the PE ratio of Fortress Biotech?
The price to earnings ratio of Fortress Biotech is -0.75
What is the cash to sales ratio of Fortress Biotech?
The cash to sales ratio of Fortress Biotech is 0.61
What is the reporting currency for Fortress Biotech?
Fortress Biotech reports financial results in USD
What is the latest annual turnover for Fortress Biotech?
The latest annual turnover of Fortress Biotech is USD 84.51M
What is the latest annual profit for Fortress Biotech?
The latest annual profit of Fortress Biotech is USD -68.67M
What is the registered address of Fortress Biotech?
The registered address for Fortress Biotech is 850 NEW BURTON ROAD, SUITE 201, KENT, DOVER, DELAWARE, 19904
What is the Fortress Biotech website address?
The website address for Fortress Biotech is www.fortressbiotech.com
Which industry sector does Fortress Biotech operate in?
Fortress Biotech operates in the PHARMACEUTICAL PREPARATIONS sector

ムーバー

すべて表示
  • 出来高
  • 値上がり率
  • 値下がり率
銘柄コード株価出来高
BTCTBTC Digital Ltd
US$ 8.2697
(73.73%)
61.45M
BDMDBaird Medical Investment Holdings Ltd
US$ 8.80
(62.36%)
18.63M
CRKNCrown Electrokinetics Corporation
US$ 0.1235
(54.96%)
764.86M
NUKKNukkleus Inc
US$ 29.97
(45.98%)
19.09M
GSITGSI Technology
US$ 3.97
(44.36%)
87.7M
DOGZDogness International Corporation
US$ 18.23
(-58.77%)
740.45k
ORKTOrangeKloud Technology Inc
US$ 3.02
(-24.88%)
21.08M
PMAXPowell Max Ltd
US$ 0.6364
(-23.31%)
4.17M
LGCBLinkage Global Inc
US$ 0.2876
(-22.27%)
890.66k
YYAIConnexa Sports Technologies Inc
US$ 0.8299
(-20.20%)
602.48k
CRKNCrown Electrokinetics Corporation
US$ 0.1235
(54.96%)
764.86M
GCTKGlucoTrack Inc
US$ 0.0852
(15.45%)
465.22M
RIMEAlgorhythm Holdings Inc
US$ 0.0406
(-4.02%)
387.23M
TGLTreasure Global Inc
US$ 0.2459
(14.75%)
267.1M
NVDANVIDIA Corporation
US$ 137.71
(3.10%)
201.4M

FBIO Discussion

投稿を表示

最近閲覧した銘柄

Delayed Upgrade Clock